regn neil stahl insider trades for regeneron pharmaceuticals inc bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close regeneron pharmaceuticals inc nasdaq regn go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus regeneron pharmaceuticals inc after hours  quotes are delayed by  min jul    pm regn quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual neil stahl dr neil stahl is executive vpresearch  development at regeneron pharmaceuticals inc he received his doctorate degree from brandeis university transactions date shares transaction value     disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      gift at  per share      gift at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      gift at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      gift at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr p roy vagelos chairman dr leonard s schleifer president chief executive officer  director mr robert e landry chief financial officer  senior vpfinance dr george damis yancopoulos director  chief scientific officer dr peter powchik senior vice presidentclinical development dr neil stahl executive vpresearch  development ms beth f levine senior vice president  chief compliance officer dr jay s markowitz senior vice presidentportfolio management mr robert j terifay senior vice presidentcommercial dr janet van adelsberg senior directorimmunology  inflammation dr alan shuldiner vice presidenttranslational genetics mr daniel p van plew svp gmindustrial operations  product supply dr n anthony coles director dr huda y zoghbi director dr bonnie l bassler director mr christopher fenimore chief accounting officer vp  controller mr potoula gjidija headmedia contacts ms hala mirza headcorporate communications dr manisha a narasimhan investor relations contact dr michael s aberman senior vpstrategy  investor relations ms sally a paull senior vice presidenthuman resources mr joseph j larosa secretary senior vice president  general counsel dr ned braunstein senior vice presidentregulatory affairs dr marc tessierlavigne independent director ms christine a poon independent director mr arthur frederick ryan independent director mr george l sing independent director dr joseph l goldstein independent director mr charles a baker independent director dr michael s brown independent class i director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money pus giving takeover bids by chinese firms much tougher look pjared kushner discloses dozens of additional assets in revised filing pbitcoin surges as miners avert split for now palphabet earnings a  billion hit for google potential youtube results for investors ahow opec committee’s coming meeting could make or break oil prices aa grandfather’s financial advice to his grandchildren loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice    neil stahl regeneron pharmaceuticals inc profile  biography  bloomberg feedback neil stahl exec vpresearch  development regeneron pharmaceuticals inc career history exec vpresearch  development regeneron pharmaceuticals present senior vpresearch  dev regeneron pharmaceuticals  senior vppreclinical devpt regeneron pharmaceuticals  vppreclinical devpt regeneron pharmaceuticals  vpbiomolecular sciences regeneron pharmaceuticals  directorcytokines  signal regeneron pharmaceuticals  show more website wwwregeneroncom corporate information address  old saw mill river road tarrytown ny  united states phone  fax  web url wwwregeneroncom from the web personal information education brandeis university phd sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data neil stahl  regeneron pharmaceuticals  inc  zoominfocom neil stahl regeneron pharmaceuticals inc svp research  development sciences  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   neil stahl svp research  development sciences regeneron pharmaceuticals inc email realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for neil stahl at regeneron pharmaceuticals inc neil stahl works as svp research  development sciences  regeneron pharmaceuticals inc is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more leads or mediamarketing prospecting automation start a free trial now recent related news  the regeneron pharmaceuticals nasdaqregn receives daily media sentiment rating of   the sale was disclosed in a document filed with the securities  exchange commission which can be accessed through this link also evp neil stahl sold  shares of the business’s stock in a transaction dated thursday june nd the shares were sold at an average price of  for a total transaction of   people in this article neil stahl  p roy vagelos  investors purchase high volume of put options on regeneron pharmaceuticals regn  equities analysts anticipate that regeneron pharmaceuticals will post  eps for the current fiscal year in other regeneron pharmaceuticals news evp neil stahl sold  shares of the stock in a transaction that occurred on thursday june nd the shares were sold at an average price of  for a total transaction of   people in this article neil stahl learn more about neil stahl and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about neil stahl and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved  npi number — neil i stahl md tweet change text size   sign in   documentation   contact us lookups soaprest api medicare payerseins crosswalks  claim form library validation all services medical data services healthcare lookup services npi lookup  npi  neil i stahl md npi number  general information text   pdf   xml    json npi number  similar providers entity type code individual provider name  organization neil i stahl md provider business mailing address copy mailing address first line  burke centre parkway  second line suite   city burke  state va  postal code zip   country us  phone   fax   provider business practice location copy practice location first line  burke centre parkway  second line suite   city burke  state va  postal code zip   country us  phone   fax   authorized official title or position   name   credential   telephone number   provider enumeration date   last updated   is this your account edit delete synchronize detailed information npi number  has the individual type of ownership and has been registered to the following primary business legal name which is a provider name or healthcare organization name — neil i stahl md records indicate that the provider gender is male the enumeration date of this npi number is  npi number information was last updated on  the provider is physically located business practice location at  burke centre parkway suite  burke va  us neil i stahl md can be reached at his practice location using the following numbers phone  fax  the providers official mailing address is  burke centre parkway suite  burke va  us the contact numbers associated with the mailing address are phone  fax  scope of practice the following information about the specialty of the provider is available  taxonomy code taxonomy specialty license number license state  rrx rheumatology  va legacy other identifiers for crosswalk purposes the following legacy nonnpi identifiers are available for this provider  provider identifier identifier type identifier state issuer  c medicare upin   medicaid va  ga medicare pin dc   other alliance geha   other va bcbs   other va tricare   other trigon fep   other aetna us healthcare   other railroad medicare  wa medicare pin va reference npi information full replica of the cms nppes npi record field name value description npi  position allnumeric identification number assigned by the nps to uniquely identify a health care provider entity type individual code describing the type of health care provider that is being assigned an npi codes are   person individual human being who furnishes health care   nonperson entity other than an individual human being that furnishes health care for example hospital snf hospital subunit pharmacy or hmo is sole proprietor n indicate whether provider is a sole proprietor a sole proprietor is the sole the only owner of a business that is not incorporated that unincorporated business is a sole proprietorship in a sole proprietorship the sole proprietor owns all of the assets of the business and is solely liable for all of the debts of the business there is no difference between a sole proprietorship and a sole proprietor they are legally a single entity an individual in terms of npi assignment a sole proprietor is an entity type  individual and is eligible for only one npi the sole proprietorship business is not eligible for its own npi as an individual a sole proprietorship cannot be a subpart and cannot have subparts see npi final rule for information about subparts a sole proprietorship may or may not have employees often the irs assigns an ein to a sole proprietorship in order to protect the sole proprietors ssn from disclosure in claims or on ws nppes does not capture a sole proprietorships ein many types of health care providers could be sole proprietorships for example group practices pharmacies home health agencies provider last name legal name stahl the last name of the provider if an individual if the provider is an individual this is the legal name this name must match the name on file with the social security administration ssa in addition the date of birth must match that on file with ssa first and last names are required for initial applications the first middle last and credentials fields allow the following special characters ampersand apostrophe colon comma forward slash hyphen left and right parentheses period pound sign quotation mark and semicolon a field cannot contain all special characters provider first name neil the first name of the provider if the provider is an individual provider middle name i the middle name of the provider if the provider is an individual provider credential text md the abbreviations for professional degrees or credentials used or held by the provider if the provider is an individual examples are md dds csw cna aa np rna or psy these credential designations will not be verified by nps provider first line business mailing address  burke centre parkway the first line mailing address of the provider being identified this data element may contain the same information as provider first line location address provider second line business mailing address suite  the second line mailing address of the provider being identified this data element may contain the same information as provider second line location address provider business mailing address city name burke the city name in the mailing address of the provider being identified this data element may contain the same information as provider location address city name provider business mailing address state name va the state or province name in the mailing address of the provider being identified this data element may contain the same information as provider location address state name provider business mailing address postal code  the postal zip or zone code in the mailing address of the provider being identified note zip code plus digit extension if available this data element may contain the same information as provider location address postal code provider business mailing address country code us the country code in the mailing address of the provider being identified this data element may contain the same information as provider location address country code provider business mailing address telephone number  the telephone number associated with mailing address of the provider being identified this data element may contain the same information as provider location address telephone number provider business mailing address fax number  the fax number associated with the mailing address of the provider being identified this data element may contain the same information as provider location address fax number provider first line business practice location address  burke centre parkway the first line location address of the provider being identified for providers with more than one physical location this is the primary location this address cannot include a post office box provider second line business practice location address suite  the second line location address of the provider being identified for providers with more than one physical location this is the primary location this address cannot include a post office box provider business practice location address city name burke the city name in the location address of the provider being identified provider business practice location address state name va the state or province name in the location address of the provider being identified provider business practice location address postal code  the postal zip or zone code in the location address of the provider being identified note zip code plus digit extension if available provider business practice location address country code us the country code in the location address of the provider being identified provider business practice location address telephone number  the telephone number associated with the location address of the provider being identified provider business practice location address fax number  the fax number associated with the location address of the provider being identified provider enumeration date  the date the provider was assigned a unique identifier assigned an npi last update date  the date that a record was last updated or changed provider gender code m the code designating the providers gender if the provider is a person provider gender male the providers gender if the provider is a person healthcare provider taxonomy code  rrx the health care provider taxonomy code is a unique alphanumeric code ten characters in length the code set is structured into three distinct levels including provider type classification and area of specialization healthcare provider taxonomy  rheumatology healthcare provider taxonomy  provider license number   certain taxonomy selections will require you to enter your license number and the state where the license was issued select foreign country in the state drop down box if the license was issued outside of united states the license number field allows the following special characters ampersand apostrophe colon comma forward slash hyphen left and right parentheses period pound sign quotation mark and semicolon a field cannot contain all special characters do not report the social security number ssn irs individual taxpayer identification number itin in this section provider license number state code  va provider license number state code  healthcare provider primary taxonomy switch  y primary taxonomy x  the primary taxonomy switch is not answered y  the taxonomy is the primary taxonomy there can be only one per npi record n  the taxonomy is not the primary taxonomy other provider identifier  c other provider identifier  other provider identifier type  medicare upin other provider identifier type  other provider identifier   other provider identifier  other provider identifier type  medicaid other provider identifier type  other provider identifier state  va other provider identifier state  other provider identifier  ga other provider identifier  other provider identifier type  medicare pin other provider identifier type  other provider identifier state  dc other provider identifier state  other provider identifier   other provider identifier  other provider identifier type  other other provider identifier type  other provider identifier issuer  alliance geha other provider identifier issuer  other provider identifier   other provider identifier  other provider identifier type  other other provider identifier type  other provider identifier state  va other provider identifier state  other provider identifier issuer  bcbs other provider identifier issuer  other provider identifier   other provider identifier  other provider identifier type  other other provider identifier type  other provider identifier state  va other provider identifier state  other provider identifier issuer  tricare other provider identifier issuer  other provider identifier   other provider identifier  other provider identifier type  other other provider identifier type  other provider identifier issuer  trigon fep other provider identifier issuer  other provider identifier   other provider identifier  other provider identifier type  other other provider identifier type  other provider identifier issuer  aetna us healthcare other provider identifier issuer  other provider identifier   other provider identifier  other provider identifier type  other other provider identifier type  other provider identifier issuer  railroad medicare other provider identifier issuer  other provider identifier  wa other provider identifier  other provider identifier type  medicare pin other provider identifier type  other provider identifier state  va other provider identifier state  driving directions to  neil i stahl md practice location these directions are for planning purposes only you may find that construction projects traffic or other events may cause road conditions to differ from the map results yours location starting point practice location destination join faq sign up about us contact us terms of use privacy policy our customers site map products  apis buy medical data cloud restsoap api  claim form to edi crosswalk services validation services npi registry trends documentation api information npi service faq rest api test drive medical coding trainer medical coding library medical coding library npi registry hcpcs directory national drug codes icdcm codes icdcm codes icd drugs  chemicals loinc codes directory msdrgs animal drug products naics code directory medical devices gudid ein directory cms forms validation services all validation services hipaaedi validation npi validation upin validation ein validation itin validation clia validation duns validation duns validation dea validation tns validation hin validation upc code validation nhric code validation lookup services npi number lookup hcpcs codes lookup ndc number lookup icd codes lookup icd codes lookup icd drugs substance lookup clia codes lookup naics codes lookup loinc codes lookup drg lookup taxonomy codes lookup animal drug products lookup global medical devices lookup pqrs quality measures lookup rxnorm concept id lookup copyright   powered by swiss vault engine all rights reserved hipaa liability trademark document use and software licensing rules apply all registered trademarks used in the content are the property of their owners your interactions with this site are in accordance with our terms of use and privacy policy the loinc table loinc codes and loinc panels and forms file are copyright   regenstrief institute inc neil i stahl md  woodbridge va  company information products resources my account talk to a db advisor  business directory va woodbridge offices and clinics of medical doctors offices and clinics of medical doctors neil i stahl md n neil i stahl md claim this business  opitz blvd woodbridge va  get directions   wwwvirginiaarthritiscom business info founded  incorporated annual revenue  employee count  industries offices and clinics of medical doctors contacts neil stahl contact business your email address subject message send message company summary since  neil i stahl md has been providing offices and clinics of medical doctors from woodbridge verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   n view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocalcom mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call  to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved regeneron pharmaceuticals inc regno people  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states regeneron pharmaceuticals inc regno related topics stocksstock screenermarket datahealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse regno on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  summary name age since current position p roy vagelos   chairman of the board leonard schleifer   president chief executive officer director robert landry   chief financial officer senior vice president  finance daniel van plew   executive vice president general manager  industrial operations and product supply neil stahl   executive vice president  research and development robert terifay   executive vice president  commercial joseph larosa   senior vice president general counsel secretary michael aberman   senior vice president  strategy and investor relation peter powchik   senior vice president  clinical development george yancopoulos   president and chief scientific officer  regeneron director christopher fenimore   vice president controller charles baker   independent director bonnie bassler   independent director michael brown   independent director n anthony coles   independent director joseph goldstein   independent director christine poon   independent director arthur ryan   independent director george sing   independent director marc tessierlavigne   independent director huda zoghbi   independent director » insider trading biographies name description p roy vagelos dr p roy vagelos md is chairman of the board of the company dr vagelos was chairman of the board and chief executive officer of merck  co inc a global pharmaceutical company he joined merck in  became a director in  president and chief executive officer in  and chairman in  dr vagelos retired from all positions with merck in  dr vagelos served on the board of directors of theravance inc through april  dr vagelos is a member of the national academy of sciences the national academy of medicine and the american philosophical society during his tenure as chairman of the company and previously as chairman and chief executive officer of merck dr vagelos developed an extensive understanding of the complex business operational scientific regulatory and commercial issues facing the pharmaceutical industry leonard schleifer dr leonard s schleifer md phd is president chief executive officer director of the company dr schleifer founded the company in  has been a director and its president and chief executive officer since its inception and served as chairman of the board from  through  dr schleifer together with regeneron’s founding scientist dr yancopoulos built and has managed the company over the past nearly  years dr schleifer is a licensed physician and is certified in neurology by the american board of psychiatry and neurology with nearly  years of experience as chief executive officer of the company dr schleifer brings to the board an incomparable knowledge of the company significant leadership experience and an indepth understanding of the complex research drug development and business issues facing companies in the biopharmaceutical industry robert landry mr robert e landry is chief financial officer senior vice president  finance of the company mr landry served as senior vice president treasurer at pfizer inc from october  to august  and senior vice president – finance pfizer’s diversified business from october  to october  prior to those roles mr landry held a number of positions at wyeth which was acquired by pfizer inc in october  including treasurer and principal corporate officer from  to  director of pharmaceutical marketing and sales of wyeth’s australian affiliate from  to  and chief financial officer of wyeth’s australian and new zealand affiliates from  to  daniel van plew mr daniel p van plew is executive vice president general manager  industrial operations and product supply of the company mr van plew served as senior vice president and general manager industrial operations and product supply prior to that date he served as vice president and general manager industrial operations and product supply since joining the company in  from  until  mr van plew served as executive vice president rd and technical operations of crucell holland bv a global biopharmaceutical company between  and  mr van plew held positions of increasing responsibility at chiron biopharmaceuticals part of chiron corporation a biotechnology company most recently as senior director vacaville operations from  until  mr van plew held various managerial positions in the health and life sciences practice at accenture ltd a management consulting business mr van plew received his ms in chemistry from the pennsylvania state university and his mba from michigan state university neil stahl dr neil stahl phd is executive vice president  research and development sciences of the company he previously served as senior vice president research and development sciences from january  to december  as senior vice president preclinical development and biomolecular sciences from december  to december  and as vice president preclinical development and biomolecular sciences from january  to december  he joined the company in  before becoming vice president biomolecular sciences in july  dr stahl was director cytokines and signal transduction dr stahl received his phd in biochemistry from brandeis university robert terifay mr robert j terifay is executive vice president  commercial of the company mr terifay was employed at several biopharmaceutical companies from january to october  mr terifay served as president and chief operating officer of arginox pharmaceuticals prior to his employment at arginox mr terifay was senior vice president business operations at synta pharmaceuticals from march to december  from february  until march  he held various senior commercial and marketing positions at millennium pharmaceuticals inc most recently as senior vice president oncology commercial mr terifay was vice president marketing at cor therapeutics inc from  until its acquisition by millennium pharmaceuticals inc in february  mr terifay was executive vice president of strategic services at saatchi  saatchi an advertising firm from  to  from  to  he held various commercial and marketing positions at gd searle  company mr terifay received his master of management degree in marketing and health service management from the jl kellogg graduate school of management northwestern university joseph larosa mr joseph j larosa is senior vice president general counsel secretary of the company mr larosa was senior vice president general counsel and secretary at nycomed us inc mr larosa’s prior experience includes working in a number of senior legal positions at scheringplough corporation from  to  where he was a corporate officer and served most recently as vice president legal affairs and a member of the operations management team mr larosa received his jd from new york university school of law michael aberman dr michael aberman md is senior vice president  strategy and investor relation of the company he served as vice president strategy and investor relations prior to joining the company he spent six years as a wall street analyst covering the biotechnology industry from march  until joining the company he was director and senior biotechnology analyst at credit suisse prior to that from march  to march  he worked as a biotechnology analyst at morgan stanley inc from february  to march  dr aberman was director of business development at antigenics inc an oncologyfocused biotechnology company dr aberman received his md with honors from the university of toronto and his mba from the wharton school of the university of pennsylvania peter powchik dr peter powchik md is senior vice president  clinical development of the company dr powchik was employed at several pharmaceutical companies serving as senior vice president and chief medical officer of chugai pharma usa a position he held from may  until october  from april  until may  he held various senior clinical development positions at novartis pharmaceuticals corporation most recently as vice president us clinical development and medical affairs dr powchik held various clinical development positions with sepracor inc and pfizer inc from october  to april  dr powchik received his md from new york university school of medicine george yancopoulos dr george d yancopoulos md phd president and chief scientific officer  regeneron director of the company dr yancopoulos joined dr schleifer in  as founding scientist of the company and together they built and have managed the company since then dr yancopoulos is currently president and chief scientific officer and has served on the board since  he received his md and phd from columbia university dr yancopoulos was the th most highly cited scientist in the world in the s and in  he was elected to be a member of the national academy of sciences dr yancopoulos together with key members of his team is a principal inventor andor developer of the five fdaapproved drugs the company has developed eylea® aflibercept injection praluent® alirocumab injection dupixent® dupilumab injection zaltrap® zivaflibercept injection for intravenous infusion and arcalyst® rilonacept injection for subcutaneous use as well as of its foundation technologies including the trap technology velocigene® and velocimmune® as one of the few members of the national academy of sciences from industry and as an author of a substantial number of scientific publications dr yancopoulos has a distinguished record of scientific expertise dr yancopoulos also brings to the board his experience in building and managing the company his indepth knowledge of the company’s technologies and research and development programs and his proven trackrecord for envisioning successful longterm strategic directions and opportunities christopher fenimore mr christopher fenimore is vice president controller of the company he served as vice president deputy controller and previously served as vice president financial planning from january  to december  prior to joining the company in  he was vice president finance at mojave therapeutics inc mr fenimore’s prior experience includes working as a supervising senior accountant at kpmg as well as healthcare industryfocused venture capital and investment banking roles mr fenimore holds an ma in biotechnology from columbia university an mba in professional accounting from rutgers business school and a ba in economics from rutgers university charles baker mr charles a baker jd is independent director of the company mr baker retired as chairman president and chief executive officer of the liposome company inc a biopharmaceutical company a position he had held since december  during his career mr baker served in a senior management capacity in various other pharmaceutical companies including tenures as group vice president squibb corporation now bristol myers squibb company and president squibb international and various senior executive positions at abbott laboratories and pfizer inc from  to  mr baker served as a member of the board of directors of progenics pharmaceuticals inc a biopharmaceutical company  bonnie bassler dr bonnie bassler phd is independent director of the company dr bassler is currently the chair of the department of molecular biology and the squibb professor in molecular biology at princeton university and a howard hughes medical institute investigator dr bassler has previously served as the president of the american society for microbiology as well as on the boards for the american association for the advancement of science the national science foundation and the american academy of microbiology she has been elected to the national academy of sciences the american academy of arts and sciences the royal society of london and the american philosophical society and has received many scientific honors including a macarthur foundation fellowship the lounsbery award and the shaw prize for life science and medicine dr bassler received her bsc from the university of california davis and her phd in biochemistry from johns hopkins university she served as a postdoctoral fellow and research scientist at the agouron institute in la jolla ca before becoming a faculty member at princeton university dr bassler served as a director of sanofi from november  to july  michael brown dr michael s brown md is independent director of the company dr brown holds the distinguished chair in biomedical sciences a position he has held since  and is a regental professor of molecular genetics and internal medicine and the director of the jonsson center for molecular genetics at the university of texas southwestern medical center at dallas positions he has held since  drs brown and goldstein jointly received the nobel prize for physiology or medicine in  and the us national medal of science in  dr brown is a member of the national academy of sciences the national academy of medicine and foreign member of the royal society of london dr brown retired as a member of the board of directors of pfizer inc in  n anthony coles dr n anthony coles md is independent director of the company dr coles has served as chairman and chief executive officer of yumanity therapeutics llc a company focused on transforming drug discovery for neurodegenerative diseases since october  prior to this from october  dr coles served as chairman and ceo of trate enterprises llc a privately held company dr coles served as president chief executive officer and chairman of the board of onyx pharmaceuticals inc a biopharmaceutical company from  until  having served as its president chief executive officer and a member of its board of directors from  until  prior to joining onyx in  he was president chief executive officer and a member of the board of directors of nps pharmaceuticals inc a biopharmaceutical company before joining nps in  he served in various leadership positions in the biopharmaceutical and pharmaceutical industries including at merck  co inc bristolmyers squibb company and vertex pharmaceuticals incorporated in addition to having previously served as a director of onyx and nps he was formerly a director of laboratory corporation of america holdings and campus crest communities inc dr coles has been a director of mckesson corporation since april  and serves on the compensation committee and the finance committee of its board of directors he has also served as chairman of the board of directors of crispr therapeutics ag since october  and serves on its compensation committee and nominating and corporate governance committee joseph goldstein dr joseph lgoldstein md is independent director of the company dr goldstein has been a professor of molecular genetics and internal medicine and the chairman of the department of molecular genetics at the university of texas southwestern medical center at dallas since  dr goldstein is a member of the national academy of sciences the national academy of medicine and the royal society of london he also serves on the boards of trustees of the rockefeller university and the howard hughes medical institute drs goldstein and brown jointly received the nobel prize for physiology or medicine in  and the us national medal of science in  christine poon ms christine a poon is independent director of the company ms poon is an executiveinresidence in the department of management and human resources at the max m fisher college of business at the ohio state university where she served as dean and the john w berry sr chair in business from  to  prior to joining fisher ms poon spent eight years at johnson  johnson most recently as vice chairman and worldwide chairman of pharmaceuticals at johnson  johnson she served on the company’s board of directors and executive committee and was responsible for managing the pharmaceutical businesses of the company prior to joining johnson  johnson ms poon spent  years at bristolmyers squibb company a global pharmaceutical company where she held senior leadership positions including president of international medicines and president of medical devices ms poon serves on the boards of directors of prudential financial inc and the sherwinwilliams company and the supervisory board of royal philips electronics arthur ryan mr arthur f ryan is independent director of the company mr ryan retired as the chairman of the board of prudential financial inc one of the largest diversified financial institutions in the world he served as chief executive officer of prudential until december  prior to joining prudential in december  mr ryan served as president and chief operating officer of chase manhattan bank since  mr ryan managed chase’s worldwide retail bank between  and  from  to  mr ryan served as a nonexecutive director of the royal bank of scotland group plc since april  mr ryan has served as a director of citizens financial group inc a retail bank holding company that became publicly traded in september  and currently serves as its lead director chair of the compensation and human resources committee and a member of the nominating and corporate governance committee george sing mr george l sing is independent director of the company mr sing has been a managing director of lancet capital a venture capital investment firm in the healthcare field from january  to april  mr sing served as chief executive officer of stemnion inc currently known as noveome biotherapeutics inc a biomedical company in the regenerative medicine field marc tessierlavigne dr marc tessierlavigne phd is independent director of the company dr tessierlavigne has been the president of stanford university since september  before assuming his role at stanford he served as the president of the rockefeller university and a carson family professor and head of the laboratory of brain development at the rockefeller university from march  previously he served as executive vice president and chief scientific officer at genentech inc which he joined in  he was a professor at stanford university from  to  and at the university of california san francisco from  to  dr tessierlavigne is a member of the national academy of sciences the national academy of medicine and a fellow of the royal societies of london and canada dr tessierlavigne is a member of the board of directors of agios pharmaceuticals inc and juno therapeutics inc and previously served on the board of directors of pfizer inc huda zoghbi dr huda y zoghbi md is independent director of the company dr zoghbi is currently a professor in the departments of pediatrics molecular and human genetics and neurology and neuroscience at baylor college of medicine the director of the jan and dan duncan neurological research institute at texas childrens hospital and an investigator of the howard hughes medical institute she has been elected to the national academy of sciences the institute of medicine and the american association for the advancement of science and has been awarded numerous recognitions for her work including the pearl meister greengard prize the march of dimes prize in developmental biology and the vanderbilt prize in biomedical science dr zoghbi earned her bsc from the american university of beirut received her md from meharry medical college in nashville tennessee and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at baylor college of medicine where she then pursued postdoctoral research training in molecular genetics basic compensation name fiscal year total p roy vagelos  leonard schleifer  robert landry  daniel van plew  neil stahl  robert terifay  joseph larosa  michael aberman  peter powchik  george yancopoulos  christopher fenimore  charles baker  bonnie bassler  michael brown  n anthony coles  joseph goldstein  christine poon  arthur ryan  george sing  marc tessierlavigne  huda zoghbi  as of   dec  options compensation name options value p roy vagelos   leonard schleifer   robert landry   daniel van plew   neil stahl   robert terifay   joseph larosa   michael aberman   peter powchik   george yancopoulos   christopher fenimore   charles baker   bonnie bassler   michael brown   n anthony coles   joseph goldstein   christine poon   arthur ryan   george sing   marc tessierlavigne   huda zoghbi   insider trading name shares traded price aberman michael s   stahl neil   stahl neil   stahl neil   stahl neil   stahl neil   stahl neil   stahl neil   aberman michael s   stahl neil   aberman michael s   aberman michael s   aberman michael s   stahl neil   aberman michael s   aberman michael s   stahl neil   stahl neil   aberman michael s   stahl neil   aberman michael s   stahl neil   aberman michael s   stahl neil   stahl neil   » full list on insider trading related topics stocksstock screenermarket datahealthcarebiotechnology  medical research ﻿ what after neil stahl’s insider unload of regeneron pharmaceuticals inc nasdaqregn stock – octafinance saturday  july  menu featured news  years ago  alphabet inc nasdaqgoogl tests its ad technology on billboards to cushion itself against ad blocks  years ago  china margin debt hits week high japan pumps’n’dumps as kyle bass fears looming em banking crisis  years ago  marc faber shares his insight in one hour exclusive interview he covers all from commodities and china to inflation the euro and gold  years ago  carl icahn criticizes the fed feels bad for investors buying junk bonds  years ago  john burbank european qe can’t save the markets same as the us quantitative easing everything will be liquidated what after neil stahl’s insider unload of regeneron pharmaceuticals inc nasdaqregn stock  by octastaff in blue chips insider news insider sells m share with your friendsyour nameyour emailrecipient emailenter a messagei read this article and found it very interesting thought it might be interesting for you the article is called what after neil stahl’s insider unload of regeneron pharmaceuticals inc nasdaqregn stock and is was published by octafinancecom at httpwwwoctafinancecomwhatafterneilstahlsinsiderunloadofregeneronpharmaceuticalsincnasdaqregnstockcaptchasubmit neil stahl insider sell transaction as shown in the us security and exchange commission a legal document for the trade of  shares of regeneron pharmaceuticals inc nasdaqregn    by neil stahl was filled neil stahl serves as a evp research and development of the new yorkbased company the legal document was filled on  the transaction’s shares were sold at average  per every share and are worth based on the market  us dollars making the trade a considerable one the chance of this stocks unloading remaining unnoticed is little because it’s significant with the evp research and development now having in hand  shares — that is   of the company’s total market capitalization regeneron pharmaceuticals inc stock rating sentiment and fundamentals it is difficult to make conclusions about regeneron pharmaceuticals inc’s future just from neil stahl’s sale because in this filing the insider also revealed option transactions in the form it was reported that neil exercised options for  shares with average price  worth  million furthermore twenty two professional stock analysts too expect a cloudy prospects of the stock exchange listed company with expected  eps and pe ratio of  they forecast year over year earnings for each share growth rate of not more than  rating  sentimentpsychsignal socialsellanalysts ratingbuyhedge funds sentimentbuy stock fundamentalsearnings  fcf trendbuysectorindustry macrobullishvaluation models technical analysisst trendupmt trenduplt trendup octafinance ratingneutral  read how our stock ratings system works regeneron pharmaceuticals inc’s stock chart indicates it has surged   in the last  days and the strong and steady up trend is expected to continue because of our tested trendfollowing model which is presented below is giving a buy our analysts can’t rate the stock sell as neil stahl did with his investment price chart of regeneron pharmaceuticals nasdaqregn stock source rightedgesystems yahoo split  dividend adjusted data and octafinance interpretations hedge funds ownership as of q   investment managers have shares of regeneron pharmaceuticals inc in the last quarter the firm had   institutional ownership that is an extremely high interest they decreased by  million the total shares they hold as of that quarter these hedge funds owned  million shares there were  funds that created new positions and  funds that added to their positions a total of  funds closed their positions in regeneron pharmaceuticals inc and  reduced their holdings regeneron pharmaceuticals inc is top  in  of them some of them are lagoda investment management lp pinnacle associates ltd ray gerald l  associates ltd sands capital management llc jw asset management llc artisan partners limited partnership ithaka group llc march altus capital management lp polen capital management llc truenorth inc boston private wealth llc had the greatest investment with ownership of  shares as of q  for  of the fund’s portfolio burnham asset management corp ny is another bullish asset manager possessing  shares of the company or  of their stocks portfolio the stock is also  of the fund’s aum the new yorkbased fund cg asset management llc have  of their stock portfolio invested in the company for  shares moreover the illinoisbased fund chesley taft  associates llc il revealed it had acquired a stake worth  of the fund’s stock portfolio in the company cypress asset management inc tx was also a notable believer in the listed company with ownership of  shares regeneron pharmaceuticals inc is  of the fund’s stock portfolio regeneron pharmaceuticals nasdaqregn company profile regeneron pharmaceuticals inc is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions the company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis ra asthma and atopic dermatitis the company’s marketed products include eylea aflibercept injection zaltrap zivaflibercept injection for intravenous infusion and arcalyst rilonacept injection for subcutaneous use the company has  product candidates in clinical development its product candidates consist of two trapbased clinical programs and  human monoclonal antibody product candidates the company has generated each of the antibodies using its velocimmune technology company website regeneron pharmaceuticals the firm has  employees at the moment its market value is  billion and it has  million outstanding shares now there are  shareholders and the institutional ownership stands at  regeneron pharmaceuticals inc was filled in new york on  the stock closed at  yesterday and it had average  days volume of  shares it is down from the  days average shares volume of  regeneron pharmaceuticals inc has a weeks low of  and a weeks high of  the stock price is above the  days simple moving average regeneron pharmaceuticals inc last issued its quarterly earnings stats on  the company reported  eps for the quarter missing the consensus estimate of  by  the company had a revenue of  billion for  and  million for  therefore the revenue was  million up  the stock option award combined incentive stock option and nonqualified stock option vests in four equal annual installments – commencing one year after the date of grant  the option became exercisable with respect to all shares underlying the option on december  –  – based upon the satisfaction by the company of certain performance criteria during the period ended december  –  regeneron pharmaceuticals  receive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with marketbeatcoms free daily email newsletter tagged neil stahlregeneron pharmaceuticals  nasdaqregn what after james koch’s insider unload of boston beer co inc nysesam stock is pacwest bancorp nasdaqpacw stock a sell after paul burke’s insider trading regeneron pharmaceuticals  get news  ratings daily enter your email address below to get the latest news and analysts ratings for regeneron pharmaceuticals with our free daily email newsletter hedge fund newstop  citadel advisors f holdings in q df dent  co inc just released its q  stock positionsmaverick capital top  holdings in q analyzing ken griffins citadel advisors stock holdings in q lone pine capital top  f positions in q guru newsfelix zulauf sees a stock market correction coming this rally sp  indexspinx will be shortlivedmarc faber shares his insight in one hour exclusive interview he covers all from commodities and china to inflation the euro and goldjim grant the next thing might be helicopter money what to buy and where he sees investment opportunitieskyle bass bearish on emerging markets for at least  more years looking to short currenciesdavid tepper gets defensive is it time to get out of the stock market macro newschina margin debt hits week high japan pumps’n’dumps as kyle bass fears looming em banking crisisare us – russian relations a zerosum gameus and russia have launched direct talks on the conflict in syriayuan drops as pboc cuts reference rate by most since devaluationcould the market crash like —put volume spike argues low is nearctas newsred rock just published report about the trend following landscape  how ctas’ performance must be analyzedhow to implement dual momentum for nonus investorsdo commodity trading advisors ctas really provide crisis alpha equity hedge and are long volatility microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates